Diversified Trust Co increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 20.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,967 shares of the pharmaceutical company’s stock after buying an additional 330 shares during the period. Diversified Trust Co’s holdings in Vertex Pharmaceuticals were worth $571,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in VRTX. OmniStar Financial Group Inc. acquired a new position in Vertex Pharmaceuticals during the 1st quarter valued at about $26,000. CX Institutional raised its position in shares of Vertex Pharmaceuticals by 103.8% in the 1st quarter. CX Institutional now owns 108 shares of the pharmaceutical company’s stock valued at $26,000 after acquiring an additional 55 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Vertex Pharmaceuticals during the 1st quarter worth approximately $28,000. Americana Partners LLC bought a new stake in Vertex Pharmaceuticals during the 4th quarter worth approximately $37,000. Finally, Advisory Alpha LLC increased its stake in Vertex Pharmaceuticals by 109.9% during the 4th quarter. Advisory Alpha LLC now owns 170 shares of the pharmaceutical company’s stock worth $39,000 after purchasing an additional 89 shares in the last quarter. Institutional investors own 93.40% of the company’s stock.
In other Vertex Pharmaceuticals news, Director Yuchun Lee sold 2,000 shares of the firm’s stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $273.16, for a total value of $546,320.00. Following the sale, the director now owns 3,875 shares of the company’s stock, valued at approximately $1,058,495. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Paul M. Silva sold 859 shares of the firm’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $248.72, for a total value of $213,650.48. Following the completion of the sale, the senior vice president now directly owns 15,791 shares in the company, valued at approximately $3,927,537.52. The disclosure for this sale can be found here. Over the last three months, insiders sold 303,424 shares of company stock worth $83,791,273. Insiders own 0.70% of the company’s stock.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, April 29th. The pharmaceutical company reported $2.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.84 by $0.72. The company had revenue of $1.52 billion for the quarter, compared to analysts’ expectations of $1.28 billion. Vertex Pharmaceuticals had a return on equity of 25.69% and a net margin of 31.35%. The business’s quarterly revenue was up 76.8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.14 earnings per share. As a group, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 7.35 EPS for the current year.
Several equities analysts have recently weighed in on VRTX shares. Guggenheim raised their price target on shares of Vertex Pharmaceuticals from $266.00 to $290.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. SunTrust Banks raised their price target on shares of Vertex Pharmaceuticals from $285.00 to $330.00 and gave the stock a “buy” rating in a research note on Wednesday, June 24th. Citigroup increased their price objective on Vertex Pharmaceuticals from $305.00 to $325.00 and gave the company a “buy” rating in a report on Friday, June 12th. Stifel Nicolaus increased their price objective on Vertex Pharmaceuticals from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Finally, Credit Suisse Group reissued a “buy” rating and issued a $298.00 price objective on shares of Vertex Pharmaceuticals in a report on Thursday, April 30th. Nine research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $285.12.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
Recommended Story: Why is cost of goods sold important?
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.